Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.49 |
| ▸ | HTR2C | P28335 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 7/20 | 0.48 |
| ▸ | HTR1A | P08908 | 6/20 | 0.48 |
| ▸ | HTR7 | P34969 | 6/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4017004 | 0.91 | HTR2A (0.51) | HTR2AHTR2CDRD2HTR1AHTR7 | |
| SCHEMBL3942876 | 0.86 | HTR2A (0.51) | HTR2AHTR2CDRD2HTR7CACNA1B | |
| SCHEMBL3941201 | 0.79 | TSHR (0.48) | HTR2AHTR2CDRD2HTR1AHTR7 | |
| SCHEMBL3561127 | 0.78 | SLC6A2 (0.57) | HTR2AHTR2CALDH1A1USP2ALOX15 | |
| SCHEMBL3568841 | 0.77 | HTR2A (0.53) | HTR2AHTR2CDRD2HTR7ALDH1A1 | |
| SCHEMBL3564522 | 0.75 | CCR3 (0.45) | HTR2ACACNA1BCACNA1CALDH1A1ALOX15 | |
| SCHEMBL3562416 | 0.72 | CCR3 (0.42) | HTR2ACACNA1BCACNA1CALDH1A1ALOX15 | |
| SCHEMBL4876820 | 0.71 | MEN1 (0.48) | HTR2AHTR2CMEN1KMT2A | |
| SCHEMBL14045161 | 0.70 | HTR1A (0.40) | HTR2AHTR2CDRD2HTR1AHTR7 | |
| SCHEMBL14997371 | 0.70 | CACNA1B (0.83) | HTR2AHTR2CDRD2HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| EP-1670470-B1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | HTR2A 119/4885HTR2C 92/4885DRD2 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.